MedTrace Logo

Early Intervention in Allergic Patients

NCT05040828 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2021-09-10

No results posted yet for this study

Summary

As many as 250 million people suffer from allergic rhinitis in China, which has a large population, early use of drugs may help better control the symptoms.This study aimed to investigate the effects of early interventional treatment with the leukotriene receptor antagonist (LTRA) montelukast on seasonal allergic rhinitis.

Conditions

  • Allergic Rhinitis Due to Weed Pollen
  • Montelukast

Interventions

BEHAVIORAL

Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.

Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.

BEHAVIORAL

Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.

10mg quaque die orally was administered after peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.

DRUG

No oral drug therapy throughout the pollen period

Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.

Sponsors & Collaborators

  • Beijing Tongren Hospital

    lead OTHER

Principal Investigators

  • Zhang Luo · Beijing Institute of Otolaryngology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2020-09-30
Completion
2020-11-10
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05040828 on ClinicalTrials.gov